Literature DB >> 18847654

Management of suspected pancreatic cystic neoplasms based on cyst size.

R Matthew Walsh1, David P Vogt, J Michael Henderson, KenZo Hirose, Travis Mason, Kalman Bencsath, Jeffrey Hammel, Nancy Brown.   

Abstract

BACKGROUND: Evaluation and management of cystic pancreatic neoplasms remain problematic. International consensus guidelines have advised resection for lesions greater than 3 cm.
METHODS: We reviewed our prospective pancreatic cystic neoplasm database for outcomes based on a cyst size of 3 cm.
RESULTS: Five hundred patients have been managed from 1999 to 2006. There were 349 patients (70%) with cysts less than or equal to 3 cm: 293 (84%) were not operated, including 243 nonmucinous cysts: 2 failed observation (0.8%, mean follow-up of 24 months). Fifty-six patients with cysts less than or equal to 3 cm were initially operated (16%), including 23 asymptomatic patients. Histopathology showed intraductal papillary mucinous neoplasm (IPMN) in 20, mucinous cystic neoplasm (MCN) in 18, and serous cystadenoma in 5. Twelve had carcinoma (21%). A total of 151 patients (30%) had cysts greater than cm: 87 (50%) were not operated, including 68 that were nonmucinous: 2 failed observation (2.9%, mean follow-up of 47 months). Sixty-four patients with cysts greater than 3 cm (42%) were initially operated, and final pathology showed MCN in 27, serous cystadenoma in 11, IPMN in 7, and pseudocyst in 7. Twelve had carcinoma (19%). Patients with cysts less than or equal to 3 cm were less likely to be operated (16 vs 42%; P < .001), less often symptomatic (39 vs 50%; P = .017), while older (mean age, 65 vs 61 years; P = .03). Had patients been managed by size alone, up to 20% would have received inappropriate treatment. Management based on aspiration was significantly better in predicting mucinous neoplasms compared with size (75% vs 57%; P < .001), including asymptomatic patients less than or equal to 3 cm (78% vs 65%; P = .003).
CONCLUSION: Size of pancreatic cystic lesions alone is not a reasonable basis for determining management.

Entities:  

Mesh:

Year:  2008        PMID: 18847654     DOI: 10.1016/j.surg.2008.06.013

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  28 in total

1.  Invasive intraductal papillary mucinous neoplasm: predictors of survival and role of adjuvant therapy.

Authors:  Olivier Turrini; Joshua A Waters; Thomas Schnelldorfer; Keith D Lillemoe; Constantin T Yiannoutsos; Michael B Farnell; Michael G Sarr; C Max Schmidt
Journal:  HPB (Oxford)       Date:  2010-09       Impact factor: 3.647

2.  851 resected cystic tumors of the pancreas: a 33-year experience at the Massachusetts General Hospital.

Authors:  Nakul P Valsangkar; Vicente Morales-Oyarvide; Sarah P Thayer; Cristina R Ferrone; Jennifer A Wargo; Andrew L Warshaw; Carlos Fernández-del Castillo
Journal:  Surgery       Date:  2012-07-06       Impact factor: 3.982

Review 3.  IPMN: surgical treatment.

Authors:  Reto M Käppeli; Sascha A Müller; Bianka Hummel; Christina Kruse; Philip Müller; Jürgen Fornaro; Alexander Wilhelm; Marcel Zadnikar; Bruno M Schmied; Ignazio Tarantino
Journal:  Langenbecks Arch Surg       Date:  2013-09-03       Impact factor: 3.445

Review 4.  Diagnosis and management of pancreatic cystic neoplasms.

Authors:  Mathew James Keegan; Bharat Paranandi
Journal:  Frontline Gastroenterol       Date:  2019-03-01

Review 5.  Management of mucinous cystic neoplasms of the pancreas.

Authors:  Mario Testini; Angela Gurrado; Germana Lissidini; Pietro Venezia; Luigi Greco; Giuseppe Piccinni
Journal:  World J Gastroenterol       Date:  2010-12-07       Impact factor: 5.742

6.  Predictive value of serum carbohydrate antigen 19-9 in malignant intraductal papillary mucinous neoplasms.

Authors:  Bin Xu; Wen-Yan Zheng; Da-Yong Jin; Wei-xing Ding; Wen-Hui Lou; Lajeswar Ramsohok
Journal:  World J Surg       Date:  2011-05       Impact factor: 3.352

7.  Cytology adds value to imaging studies for risk assessment of malignancy in pancreatic mucinous cysts.

Authors:  Muriel Genevay; Mari Mino-Kenudson; Kurt Yaeger; Ioannis T Konstantinidis; Cristina R Ferrone; Sarah Thayer; Carlos Fernandez-del Castillo; Dushyant Sahani; Brenna Bounds; David Forcione; William R Brugge; Martha Bishop Pitman
Journal:  Ann Surg       Date:  2011-12       Impact factor: 12.969

Review 8.  Management of mucin-producing cystic neoplasms of the pancreas.

Authors:  Stefan Fritz; Andrew L Warshaw; Sarah P Thayer
Journal:  Oncologist       Date:  2009-02-11

9.  Natural history of asymptomatic pancreatic cystic neoplasms.

Authors:  Gareth Morris-Stiff; Gavin A Falk; Sricharan Chalikonda; R Matthew Walsh
Journal:  HPB (Oxford)       Date:  2012-07-23       Impact factor: 3.647

Review 10.  Malignant potential of intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Yoshiyuki Nakajima; Takatsugu Yamada; Masayuki Sho
Journal:  Surg Today       Date:  2010-08-26       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.